Furthermore, our in vitro data supported the finding that SIRT1 overexpression markedly hampered HRAS-induced tumorigenic activities, indicating SIRT1 as a tumor suppressor in the oncogenic RAS activation setting as well. The gene discussed is HRAS; the disease is neoplasm.